{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:50:28Z","timestamp":1790905828393,"version":"4.1.0"},"reference-count":50,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2016,11,10]]},"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Currently available analgesics are ineffective in 30\u201350% of patients suffering from neuropathic pain and often induce deleterious side effects. T-type calcium channel blockers (mibefradil, ethosuximide, NNC 55-0396) are of great interest for the development of new symptomatic treatments of neuropathic pain, due to their various effects on pain perception. Interestingly, ethosuximide, which has already been approved for treating epilepsy, is available on the European market for clinical use. Despite numerous preclinical data demonstrating an antinociceptive effect of ethosuximide in various animal models of neuropathic pain, no clinical studies have been published to date on the analgesic efficacy of ethosuximide in patients with neuropathic pain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>The Ethosuximide in the Treatment of non-Diabetic Peripheral Neuropathic Pain (EDONOT) trial is a randomised, parallel, controlled, double-blinded, multicentre clinical study. It is the first clinical trial to evaluate the efficacy and safety of ethosuximide in the treatment of non-diabetic peripheral neuropathic pain. Adult patients exhibiting peripheral neuropathic pain (Numeric Rating Scale (NRS) \u22654 and Douleur Neuropathique 4 (DN4)\u22654) for at least 3\u2005months and under stable analgesic treatment for at least 1\u2005month will be included. Patients (n=220) will be randomly assigned to receive either ethosuximide or control treatment for 6\u2005weeks following a 1\u2005week run-in period. The primary end point is the intensity of neuropathic pain, assessed by NRS (0\u201310) before and after 6\u2005weeks of treatment. The secondary end points are safety (adverse events are collected during the study: daily by the patient on the logbook and during planned phone calls by investigators), the intensity and features of neuropathic pain (assessed by Brief Pain Inventory (BPI) and Neuropathic Pain Symptom Inventory (NPSI) questionnaires) and health-related quality of life (assessed by Medical Outcome Study Short Form 12 (MOS SF-12) and Leeds questionnaires).<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and communication<\/jats:title><jats:p>The study was approved by an independent ethics committee (CPP Sud-Est VI, France, IRB00008526) and registered by the French competent authority (Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament (ANSM)).<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02100046?term=ethosuximide&amp;rank=1\" ext-link-type=\"uri\">NCT02100046<\/jats:ext-link>, Recruiting.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2016-013530","type":"journal-article","created":{"date-parts":[[2016,12,24]],"date-time":"2016-12-24T18:35:38Z","timestamp":1482604538000},"page":"e013530","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Assessment of the effectiveness and safety of Ethosuximide in the Treatment of non-Diabetic Peripheral Neuropathic Pain: EDONOT\u2014protocol of a randomised, parallel, controlled, double-blinded and multicentre clinical trial"],"prefix":"10.1136","volume":"6","clinical-trial-number":[{"clinical-trial-number":"nct02100046","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Nicolas","family":"Kerckhove","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Mallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chouki","family":"Chenaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Duale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Dubray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Eschalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,12,16]]},"reference":[{"key":"2024051611310498000_6.12.e013530.1","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00424-014-1484-4","article-title":"T-type calcium channels in chronic pain: mouse models and specific blockers","volume":"466","author":"Fran\u00e7ois","year":"2014","journal-title":"Pfl\u00fcgers Arch"},{"key":"2024051611310498000_6.12.e013530.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70251-0"},{"key":"2024051611310498000_6.12.e013530.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2007.08.013"},{"key":"2024051611310498000_6.12.e013530.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2008.03.002"},{"key":"2024051611310498000_6.12.e013530.5","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1399-6576.2007.01486.x","article-title":"Prevalence of self-reported neuropathic pain and impact on quality of life: a prospective representative survey","volume":"52","author":"Gustorff","year":"2008","journal-title":"Acta Anaesthesiol Scand"},{"key":"2024051611310498000_6.12.e013530.6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ajem.2009.07.009","article-title":"Prevalence of neuropathic pain in emergency patients: an observational study","volume":"29","author":"Lecomte","year":"2011","journal-title":"Am J Emerg Med"},{"key":"2024051611310498000_6.12.e013530.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2005.11.008"},{"key":"2024051611310498000_6.12.e013530.8","first-page":"918","article-title":"The prevalence and impact of chronic pain with neuropathic pain symptoms in the general population","volume":"10","author":"Toth","year":"2009","journal-title":"Pain Med Malden Mass"},{"key":"2024051611310498000_6.12.e013530.9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010364"},{"key":"2024051611310498000_6.12.e013530.10","doi-asserted-by":"publisher","DOI":"10.1038\/36110"},{"key":"2024051611310498000_6.12.e013530.11","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.83.1.103"},{"key":"2024051611310498000_6.12.e013530.12","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1523\/JNEUROSCI.19-06-01912.1999","article-title":"Cloning and expression of a novel member of the low voltage-activated T-type calcium channel family","volume":"19","author":"Lee","year":"1999","journal-title":"J Neurosci"},{"key":"2024051611310498000_6.12.e013530.13","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00018.2002"},{"key":"2024051611310498000_6.12.e013530.14","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ph.58.030196.001553"},{"key":"2024051611310498000_6.12.e013530.15","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7600515"},{"key":"2024051611310498000_6.12.e013530.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2005.08.017"},{"key":"2024051611310498000_6.12.e013530.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2012.10.023"},{"key":"2024051611310498000_6.12.e013530.18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1100869108"},{"key":"2024051611310498000_6.12.e013530.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2014.01.015"},{"key":"2024051611310498000_6.12.e013530.20","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1989.sp017705"},{"key":"2024051611310498000_6.12.e013530.21","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.75.1.144"},{"key":"2024051611310498000_6.12.e013530.22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0026-895X(24)12624-7","article-title":"Ca(v)3.2 channel is a molecular substrate for inhibition of T-type calcium currents in rat sensory neurons by nitrous oxide","volume":"60","author":"Todorovic","year":"2001","journal-title":"Mol Pharmacol"},{"key":"2024051611310498000_6.12.e013530.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(03)00177-5"},{"key":"2024051611310498000_6.12.e013530.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.01.029"},{"key":"2024051611310498000_6.12.e013530.25","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8069-8-7"},{"key":"2024051611310498000_6.12.e013530.26","doi-asserted-by":"publisher","DOI":"10.2337\/db08-1763"},{"key":"2024051611310498000_6.12.e013530.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2009.06.012"},{"key":"2024051611310498000_6.12.e013530.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2005.00326.x"},{"key":"2024051611310498000_6.12.e013530.29","unstructured":"Katzung . Drugs used in generalized seizures. In: Basic and Clinical Pharmacology. 9th edn. UK: Mcgraw Hill Companies, 2003."},{"key":"2024051611310498000_6.12.e013530.30","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410250610"},{"key":"2024051611310498000_6.12.e013530.31","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(89)90376-5"},{"key":"2024051611310498000_6.12.e013530.32","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1152\/jn.1998.79.1.240","article-title":"Pharmacological properties of T-type Ca2+ current in adult rat sensory neurons: effects of anticonvulsant and anesthetic agents","volume":"79","author":"Todorovic","year":"1998","journal-title":"J Neurophysiol"},{"key":"2024051611310498000_6.12.e013530.33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0708930105"},{"key":"2024051611310498000_6.12.e013530.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2007.03.005"},{"key":"2024051611310498000_6.12.e013530.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.12.010"},{"key":"2024051611310498000_6.12.e013530.36","first-page":"CD008242","article-title":"Amitriptyline for neuropathic pain and fibromyalgia in adults","volume":"12","author":"Moore","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2024051611310498000_6.12.e013530.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(98)00109-7"},{"key":"2024051611310498000_6.12.e013530.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2003.12.024"},{"key":"2024051611310498000_6.12.e013530.39","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singap"},{"key":"2024051611310498000_6.12.e013530.40","doi-asserted-by":"publisher","DOI":"10.1007\/BF00434408"},{"key":"2024051611310498000_6.12.e013530.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmpt.2003.11.003"},{"key":"2024051611310498000_6.12.e013530.42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.02979.x"},{"key":"2024051611310498000_6.12.e013530.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67177-2"},{"key":"2024051611310498000_6.12.e013530.44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)02293-9"},{"key":"2024051611310498000_6.12.e013530.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2007.08.033"},{"key":"2024051611310498000_6.12.e013530.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.06.019"},{"key":"2024051611310498000_6.12.e013530.47","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000259085.61898.9e"},{"key":"2024051611310498000_6.12.e013530.48","doi-asserted-by":"publisher","DOI":"10.1053\/eujp.2001.0259"},{"key":"2024051611310498000_6.12.e013530.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.02.034"},{"key":"2024051611310498000_6.12.e013530.50","first-page":"113","article-title":"A burden of illness study for neuropathic pain in Europe","volume":"8","author":"Liedgens","year":"2016","journal-title":"Clin Outcomes Res"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2016-013530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T21:31:43Z","timestamp":1749850303000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2016-013530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12,16]]},"published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1136\/bmjopen-2016-013530"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2016-013530","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}